Previous Article | Next Article 
Applied and Environmental Microbiology, October 2003, p. 5870-5874, Vol. 69, No. 10
0099-2240/03/$08.00+0 DOI: 10.1128/AEM.69.10.5870-5874.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
Mycotoxin Fumonisin B1 Increases Intestinal Colonization by Pathogenic Escherichia coli in Pigs
Isabelle P. Oswald,1* Clarisse Desautels,2 Joëlle Laffitte,1 Sylvie Fournout,1,2 Sylvie Y. Peres,2 Marielle Odin,2 Pierrette Le Bars,1 Joseph Le Bars,1 and John M. Fairbrother2
Laboratoire de Pharmacologie-Toxicologie, Institut National de la Recherche Agronomique, Toulouse, France,1
GREMIP, Faculté de Médecine Vétérinaire, Université de Montréal, Saint Hyacinthe, Québec, Canada2
Received 31 January 2003/
Accepted 21 July 2003
 |
ABSTRACT
|
|---|
Fumonisin
B1 (FB1) is a mycotoxin that commonly occurs in
maize. FB1 causes a variety of toxic effects in different
animal species and has been implicated as a contributing factor of
esophageal cancers in humans. In the present study, we examined the
effect of dietary exposure to FB1 on intestinal colonization
by pathogenic Escherichia coli associated with extraintestinal
infection. Three-week-old weaned pigs were given FB1 by
gavage as a crude extract or as a purified toxin at a dose of 0.5 mg/kg
of body weight daily for 6 days. On the last day of the toxin
treatment, the pigs were orally inoculated with an extraintestinal
pathogenic E. coli strain. All animals were euthanized
24 h later, necropsies were performed, and tissues were taken
for bacterial counts and light microscopic examination. Ingestion of
FB1 had only a minimal effect on animal weight gain, did not
cause any macroscopic or microscopic lesions, and did not change the
plasma biochemical profile. However, colonization of the small and
large intestines by an extraintestinal pathogenic E. coli
strain was significantly increased. Our results show that
FB1 is a predisposing factor to infectious disease and that
the pig can be used as a model for the study of the consequences of
ingesting mycotoxin-contaminated
food.
 |
INTRODUCTION
|
|---|
Mycotoxins are secondary metabolites of fungi which may contaminate
animal and human feeds at all stages of the food chain.Their global occurrence is considered an important risk factor for
human and animal health, as up to 25% of the world crop
production may be contaminated with mycotoxins
(16,
31).
Fumonisin
B1 (FB1) belongs to the fumonisin family of
toxins (4) which are
produced by Fusarium verticillioides and Fusarium
proliferatum, fungi that commonly contaminate maize. Recent
surveys of fumonisins in food and feed throughout the world, including
the United States and most European countries, raised concerns about
the extent of FB1 contamination of maize and its
implications for food safety
(13,
52,
53). FB1 was
found in up to 50% of maize samples collected between 1988 and
1991 from the midwestern United States
(41). In this survey, up
to 10% of the samples had toxin levels between 10 and 50 ppm
(41). Similarly, another
survey of fumonisins in maize gluten and other maize products in the
United Kingdom found these mycotoxins in almost every sample at
concentrations of up to 32 ppm
(52).
At high
concentrations (50 to 500 ppm), FB1 causes a variety of
species-specific toxicological effects in domestic and laboratory
animals. It induces leukoencephalomalacia in horses, pulmonary edema in
pigs, and nephrotoxicity in rats, rabbits, lambs, and calves
(3,
14,
21,
22,
32,
54). In all species
studied, both acute and chronic exposure to FB1 are
associated with alteration of sphingolipid metabolism and
hepatotoxicity (9,
20,
21,
26,
44,
46,
48). FB1 also
has been implicated as a contributing factor in human esophageal
cancers (45) and is a
renal and hepatic carcinogen in male and female rats, respectively
(22). The mechanism(s) of
toxicity for fumonisins is complex and may involve several molecular
sites (47). The primary
biochemical effect of fumonisin is to inhibit ceramide synthase
activity, leading to the accumulation of sphingoid bases
and sphingoid base metabolites and the depletion of more complex
sphingolipids
(36).
Although
Escherichia coli is a normal inhabitant of the intestinal
flora, it is frequently associated with both intestinal and
extraintestinal infections. Extraintestinal pathogenic E. coli
(ExPEC) strains usually possess virulence determinants that allow them
to persist in the intestine, cross epithelial barriers, resist
nonspecific host defense mechanisms, establish specifically in
extraintestinal tissues, and potentially cause damage at these sites
(50,
55). For instance, ExPEC
strains with similar virulence determinants have been associated with
urinary tract diseases in humans and septicemia in pigs
(7,
15,
23). We have established
a septicemia model involving oral inoculation of porcine ExPEC strains
in newborn, colostrum-deprived, germfree pigs to study the pathogenic
mechanisms of these bacteria in the natural host when it is highly
susceptible to bacterial infection
(17). These bacteria are
also opportunistic pathogens, as they have been found in the intestines
of healthy older pigs
(19), dogs
(23), and humans
(7). Host conditions,
therefore, are of critical importance in the ability of bacteria to
infect and colonize the host and cause disease
(34,
38,
42,
58).
The intestinal
tract is the first barrier to ingested mycotoxins but is also the first
line of defense against intestinal infection. Ingestion of some
mycotoxins increases susceptibility to experimental or natural mucosal
infections (18,
56,
57), but no data are
available concerning the effect of fumonisin as a predisposing factor
to intestinal infections. The objective of the present study was to
determine the effect of dietary exposure to low doses of FB1
on intestinal colonization by the pathogenic bacterium E.
coli.
 |
MATERIALS AND
METHODS
|
|---|
Animals.
Thirty-five 3-week-old weaned healthy
male Yorkshire hybrid pigs were used for the experiments. They were
acquired locally at 2 weeks of age, just after weaning, and
acclimatized for 1 week in the isolation rooms of the animal care
facilities of the Faculté de Médécine
Vétérinaire, Université de Montréal, at an
ambient temperature of 24°C. The pigs were weighed daily. They
had free access to water and were fed a commercial starter diet, free
of FB1, throughout the experiment. Animals were cared for in
accordance with guidelines of the Canadian Council for Animal
Care.
Toxin.
In a first experiment, the mycotoxin
was administered as a crude extract obtained after in vitro culture.
Briefly, sterilized crushed maize (50% water content) was
inoculated with the high FB1-producing F.
verticillioides strain NRRL 34281 (deposited in the ARS Culture
Collection, Peoria, Ill.). The fungal strain was incubated for 4 weeks
at 25°C. This culture was extracted with acetonitrile-water
(1:1), filtered, and concentrated with a rotary evaporator. The culture
extract contained 1.4 g of FB1/liter.
The
FB1 concentration was measured by quantitative planar
chromatography (28).
Briefly, after a two-step thin-layer chromatography development, the
plates were visualized with p-anisaldehyde. This planar
chromatography technique has a detection limit of 50 ng
(28). The culture extract
used in this preparation did not produce detectable amounts of the
following fusariotoxins: zearalenone, deoxynivalenol, fusarochromanone,
and trichothecene (12,
39). Purified
FB1 obtained from PROMEC (Tygerberg, South Africa) was used
for the second experiment. This toxin (purity, >95%) was
extracted and purified according to the method of Cawood
(8).
Bacterial
isolate.
Piglets were
inoculated with an ExPEC strain designated 28CNalr
(O75:K95). This strain possesses pap, sfa,
hly, cnf-1, and aerobactin genomic sequences, as
determined by colony hybridization and produces CNF1, alpha-hemolysin,
and P and F1C fimbriae
(10). It is a
Nalr variant of strain 28C
(10) that was obtained by
serial passage of 28C following growth in Luria broth containing
concentrations of nalidixic acid from 0 to 50 µg/ml at
37°C for 24 h. This strain was deposited in the
Pasteur Institute Collection under the designation CIP
107983.
General experimental
protocol.
Two experiments
were performed with the same protocol. For 6 days, treated pigs were
given by gavage 0.5 mg of FB1/kg of body weight/day as a
crude extract (experiment 1) or as a purified toxin (experiment 2).
Based on average feed consumption for piglets of this age, the dose
used (0.5 mg/kg/day) corresponds to feed contaminated with 5 to 8 ppm
of FB1. The crude extract was given undiluted to the
piglets. The purified toxin was diluted in sterile water to a final
concentration of 1 mg/ml and given in a volume of 3 to 5 ml according
to the animal weight. Control animals received 4 ml of sterile water.
On the last day of toxin treatment, half of the pigs within each group
were orally inoculated with 1 x 109 to 1.1 x
109 CFU of strain 28CNalr. Pigs received 10 ml of
1.2% NaHCO3 through an intragastric tube to
neutralize gastric acid, followed by 20 ml of tryptic soy broth (Difco
Laboratories, Detroit, Mich.) containing the bacteria. Control,
noninfected animals were treated similarly, receiving NaHCO3
plus tryptic soy broth.
Twenty-four hours after bacterial
inoculation, the pigs were euthanized with an intracardiac injection of
sodium pentobarbital (Euthanyl Forte; Biomedia-MTC,
Cambridge, Ontario, Canada; 540 mg/ml diluted in 0.20 ml of propylene
glycol). Following exsanguination, a complete necropsy was performed
and standard samples of the lung, liver, spleen, kidney, duodenum,
jejunum, ileum, cecum, colon, and mesenteric lymph nodes (at the level
of the ileum) were collected. These samples were consistently taken
from the same areas of the respective organs in all animals.
A
portion of each tissue was placed on ice and used immediately for
bacteriological examination
(17). A second portion
was immersed in 10% neutral buffered formalin for
histopathology.
Bacteriological
counts.
Tissues were
evaluated quantitatively for the presence of E. coli. Samples
were weighed and suspended in 2 ml of phosphate-buffered saline,
homogenized at 5,000 rpm with a Cat homogenizer model X120
(PolyScience, Niles, Ill.), and serially diluted 10-fold in
sterile phosphate-buffered saline. Dilutions were plated on tryptic soy
agar (Difco) supplemented with 0.2% nalidixic acid with a spiral
plater system model C (Meyer Service and Supply, Ltd., Long Sault,
Canada) as recommended by the manufacturer. After overnight incubation
at 37°C, bacterial colonies were counted with a minimum of 1
colony per plate. Several colonies from each individual were positively
identified as the infecting strain by PCR and agglutination
tests.
Histopathology.
Tissue samples, fixed in 10%
neutral buffered formalin, were embedded in paraffin, sectioned at
approximately 5-µm intervals, and stained with hematoxylin and
phloxine saffron for examination by light microscopy.Bacterial localization in intestinal and extraintestinal tissues was
determined by immunohistochemistry. Sections were stained with Vector
red (Vector Laboratories, Burlington, Canada) and examined by light
microscopy as previously described
(17) by using rabbit
polyclonal anti-O75 serogroup
serum.
Biochemical analysis.
At the time of necropsy, blood was
collected on EDTA for plasma biochemical analysis (Biochemistry
Laboratory, Rangueil Hospital, Toulouse, France). The analysis included
determinations of creatinine, urea nitrogen, total protein, calcium,
phosphorus, sodium, potassium, chloride, glucose, cholesterol, total
bilirubin, alkaline phosphatase, aspartate aminotransferase, alanine
aminotranferase, lactate dehydrogenase, and gamma-glutamyl
transferase.
Statistical
analysis.
Student's
t test and analysis of variance (ANOVA) were used to analyze
weight gain and bacterial counts. P values of <0.05
were considered
significant.
 |
RESULTS
|
|---|
Effect
of FB1 on weight gain.
Separate experiments were performed
using FB1 as either a crude extract or purified toxin. We
first examined the effect of 0.5 mg of FB1/kg of body weight
on clinical signs and animal performance. Pigs receiving
FB1, either as a crude extract or as the purified toxin,
appeared clinically normal throughout the study, and no deaths
occurred. Pigs in the FB1-treated groups did not gain as
much weight as those in the control group, but the difference was not
statistically significant (Table
1). At necropsy, no gross changes were considered to be related to the
administration of FB1. Microscopic lesions not usually
associated with FB1 toxicity, including nonspecific
superficial colitis and a mostly mild interstitial pneumonia with a
mononuclear cell infiltration, were sometimes observed, although to
similar extents in pigs of both groups. No microscopic lesions
considered to be compatible with FB1 toxicity, such as
apoptosis, were observed during examination of liver and other tissues
following routine hematoxylin and phloxine saffron staining in
FB1-treated pigs. Plasma biochemical analysis did not reveal
any effect of FB1 (data not
shown).
Effect of FB1 on
bacterial colonization.
In
control pigs from experiment 1 (Table
2, experiment 1), strain 28CNalr was recovered in low numbers
from the intestine, colonizing mostly the cecum and the colon. Very few
bacteria were translocated to the mesenteric lymph nodes or
disseminated to extraintestinal organs. Of the five inoculated pigs,
strain 28CNalr was recovered from an extraintestinal organ
of only one pig, this being the lung. When pigs were treated with
FB1 administered as a crude extract, 28CNalr
colonized the examined tissues to a greater extent than it did in
untreated animals (Table
2, experiment 1). We
recovered 400- to 700-fold more CFU of the inoculated strain per gram
of tissue from the intestines of treated animals than from animals that
had received no fumonisin. In three of the four FB1-treated
pigs, bacteria were translocated to the mesenteric lymph nodes and
disseminated to the lungs. In one pig, bacteria of strain
28CNalr were also found in the liver and the
spleen.
View this table:
[in this window]
[in a new window]
|
TABLE 2. Effect
of oral administration of FB1 on bacterial colonization of
piglet intestines by E. coli strain 28CNalr
|
|
To confirm that the increase in susceptibility of the
pigs to E. coli infection was due to FB1, the
experiment was repeated with purified mycotoxin (Table
2, experiment 2). As
expected, greater intestinal colonization was observed in
FB1-treated pigs than in the untreated animals. However, in
this experiment, the bacteria translocated poorly to extraintestinal
organs, and E. coli 28C was recovered only from the mesenteric
lymph nodes of two out of five FB1-treated pigs.
Based
on immunohistochemistry with Vector red, red-stained bacteria were
often observed in the lumen and in close contact with the intestinal
mucosal surface and in the serosa, mostly of the cecum and colon, of
FB1-treated pigs (Fig.
1A). Similar red-stained bacteria were occasionally observed in the lumen,
but only rarely were they in contact with the mucosa or in the serosa
of the intestines of untreated animals (Fig.
1B).

View larger version (90K):
[in this window]
[in a new window]
|
FIG. 1. In
situ visualization of bacteria in colon tissue by immunohistochemistry
using an anti-O75 serum and Vector red staining. Piglets were treated
with FB1 (A), or left untreated (B), inoculated with E.
coli strain 28CNalr, and euthanized 24 h
postinoculation. (A) Bacteria, stained red on direct
microscopic observation, were found in aggregates closely associated
with the colon surface epithelium (arrow) and in the serosa
(arrowhead). (B) Similar bacteria were occasionally found
individually associated with the colon surface epithelium (arrow) but
not in the serosa. Bar size, 100
µm.
|
|
 |
DISCUSSION
|
|---|
Ingestion
of FB1 increased intestinal colonization by E. coli
strain 28CNalr. This bacterial strain can persist in the
large intestine of pigs under normal conditions and can colonize the
gut and translocate to internal organs when the immune system is
compromised, e.g., in the absence of colostrum in conventional or
germfree newborn pigs (J. M. Fairbrother, unpublished
results). It is possible that a similar effect occurs in older animals
when other agents, e.g., mycotoxins, affect the intestinal tract and/or
the immune system. The low pathogenicity of this strain is also
reflected by its poor ability to elicit an inflammatory response in the
intestines, as demonstrated by the absence of an inflammatory cell
infiltrate (Fig. 1), and
of the induction of RNA encoding inflammatory cytokines (data not
shown). Since strains of this pathotype are also recovered from
patients with urinary tract infections, strain 28CNalr
appears to typify opportunistic ExPEC organisms.
The dose of
FB1 administered to pigs in our experiments (0.5 mg of
FB1/kg of body weight, equivalent to 5 to 8 ppm in the feed)
significantly increased the bacterial colonization of the intestine
(Table 2); however, this
dose did not induce clinical or pathological changes and had no
significant impact on weight gain. Using the same concentration of
FB1, but for a longer period of time (8 weeks), Rotter et
al. (49) reported an
11% decrease in daily weight gain of pigs, and a 31%
decrease in weight was observed in pigs fed a high dose (20 mg/kg of
body weight) of FB1 for 7 days
(54). The toxic dose of
FB1 depends upon the animal species and parameters
investigated. In pigs, changes in serum sphingolipids are detected at 5
ppm of FB1
(46), liver damage occurs
at 23 ppm (40), and
pulmonary edema occurs at 175 ppm
(40). Clinical chemistry
profiles indicate that alkaline phosphatase is the most sensitive
measure of fumonisin toxicity in pigs
(20,
40,
46). The dose and the
time exposure used in our study did not induce any change in serum
biochemical parameters (data not shown) but did significantly increase
bacterial colonization by pathogenic E. coli. Several
researchers have described an alteration of biochemical values in pig
serum, but these were obtained with higher doses of toxin
(54), longer exposure
(49,
60), or both
(40,
59).
We found that
FB1 increases bacterial colonization in the intestines of
piglets. Interestingly, the difference in bacterial colonization
between the FB1-treated and the control (untreated) pigs was
greater in the first experiment than in the second one (Table
2). This result may be due
to an unidentified compound present in the culture material that was
acting synergistically with FB1. Alternatively, the
difference in the initial weights of the pigs might have had an impact.
The administration of similar bacterial loads to pigs in the first
experiment, who had lower body weights, and consequently smaller
intestines than pigs in the second experiment, may have resulted in the
presence in the intestinal lumen of a greater number of bacteria
relative to the lumen size and thereby may have exacerbated the effect
of FB1 on intestinal colonization.
Several mycotoxins
can alter the immune response and increase susceptibility to infectious
disease (33,
42,
57), and sublethal
concentrations of FB1 decrease bacterial clearance after
intravenous infections
(29,
54). However, a recent
paper (11) indicates that
diets contaminated with 50 or 150 ppm of FB1 enhance the
resistance of mice to parasitic infection. There are a few reports on
the influence of mycotoxins on intestinal colonization by pathogenic
bacteria; however, none of these reports evaluated fumonisin. Fukata et
al. (18) reported
increased intestinal colonization by Salmonella enterica
serovar Typhimurium in 11-day-old chickens fed high doses of ochratoxin
A, although Kubena et al.
(27), using the same
model, observed no effects attributable to either aflatoxin or T-2
toxin.
FB1 specifically inhibits ceramide synthase
activity, resulting in the disruption of sphingolipid metabolism
(35,
48).Sphingolipids and sphingoglycolipids are essential components of
eukaryotic cell membranes, and these molecules may act as membrane
receptors for bacteria (2,
5,
24) and bacterial toxins
(30,
51). Thus, ingestion of
FB1 may induce sphingolipid changes in the gastrointestinal
tract and modify bacterial receptors on the surfaces of epithelial
cells. These changes may contribute to the increased colonization of
the intestinal tract by pathogenic bacteria.
We used pigs in this
study for at least three reasons. First, due to their maize-rich diet,
pigs are potentially exposed to high levels of fumonisins. From a
public health perspective, increased colonization of the pig intestine
by potentially pathogenic E. coli following the ingestion of
fumonisin may increase animal-to-human transmission of pathogens and/or
increased antibiotic concentrations in meat as a consequence of animal
treatment. Second, rodents are very resistant to most mycotoxins
(25,
37) and are not available
as models. Finally, pigs and humans have many biological similarities,
especially with regard to the intestinal tract
(1,
6,
43), which makes the pig
a good model for the study of the consequences of ingestion of
mycotoxin-contaminated food.
In conclusion, we found that
exposure to FB1 is a predisposing factor to infectious
disease. Considering the high levels of FB1 that may be
present in animal feeds and human food preparations
(41,
52,
53), further studies are
needed to identify the mechanism(s) by which this mycotoxin acts on the
intestinal tract to modulate colonization by opportunistic pathogens.
Epidemiological studies are also needed to assess the extent to which
fumonisins are involved in the development of infectious diseases in
humans and animals.
 |
ACKNOWLEDGMENTS
|
|---|
Sylvie Fournout and Sylvie
Pérès were supported by the Natural Sciences and
Engineering Research Council (NSERC) of Canada, grant GPG0181728, and
by the Ministère de l'Éducation du Québec,
respectively. Marielle Odin was supported by NSERC grant 2294.
We
thank Francis Girard for assistance in preparation of photographs. This
work was supported in part by the Programme Environnement et
Santé EN98-27 of the Ministère de l'Aménagement
du Territoire et de l'Environnement, Paris, France, by
the région Midi-Pyrénées (DAER-Rech/99008345), and by
the Transversalité INRA
(Mycotoxines-P00263).
 |
FOOTNOTES
|
|---|
* Corresponding author. Mailing address: Laboratoire de Pharmacologie Toxicologie, INRA, 180 Chemin de Tournefeuille, 31931 Toulouse Cedex 9, France. Phone: 33 (0) 561285480. Fax: 33 (0) 561285310. E-mail: ioswald{at}toulouse.inra.fr. 
 |
REFERENCES
|
|---|
- Almond,
G. W. 1996. Research applications using
pigs. Vet. Clin. N. Am. Food Anim. Pract.
12:707-716.[Medline]
- Backhed,
F., B. Alsen, N. Roche, J. Angstrom, A. von Euler, M. E.
Breimer, B. Westerlund-Wikstrom, S. Teneberg, and A.
Richter-Dahlfors. 2002. Identification of target
tissue glycosphingolipid receptors for uropathogenic, F1C-fimbriated
Escherichia coli and its role in mucosal inflammation.J. Biol. Chem.
277:18198-18205.[Abstract/Free Full Text]
- Bane,
D. P., E. J. Neumann, W. F. Hall,
K. S. Harlin, and R. L. Slife.1992
. Relationship between fumonisin contamination of feed
and mystery swine disease. A case-control study.Mycopathologia
117:121-124.[CrossRef][Medline]
- Bezuidenhout,
S. C., W. C. A. Gelderblom, C.
P. Gorst-Alleman, R. M. Horak, W. F. O.
Marasas, G. Spiteller, and R. Vleggaar. 1988.
Structure elucidation of the fumonisin, mycotoxins from Fusarium
moniliforme. J. Soc. Chem. Commun.
1988:743-745.
- Bibel,
D. J., R. Aly, and H. R. Shinefield.1992
. Inhibition of microbial adherence by sphinganine.Can. J. Microbiol.
38:983-985.[Medline]
- Bondy,
G. S., and J. J. Pestka. 2000.
Immunomodulation by fungal toxins. J. Toxicol. Environ. Health
B
3:109-143.
- Brauner,
A., M. Katouli, K. Tullus, and S. H. Jacobson.1990
. Production of cytotoxic necrotizing factor,
verocytotoxin and haemolysin by pyelonephritogenic Escherichia
coli. Eur. J. Clin. Microbiol. Infect.
Dis.
9:762-767.[CrossRef][Medline]
- Cawood,
M. E. 1991. Isolation of the fumonisin
mycotoxins: a quantitative approach. J. Agric. Food
Chem.
39:1958-1962.[CrossRef]
- Colvin,
B. M., and L. R. Harrison. 1992.
Fumonisin-induced pulmonary edema and hydrothorax in swine.Mycopathologia
117:79-82.[CrossRef][Medline]
- Dozois,
C. M., S. Clément, C. Desautels, E. Oswald, and
J. M. Fairbrother. 1997. Expression of P, S,
and F1C adhesins by cytotoxic necrotizing factor 1-producing
Escherichia coli from septicemic and diarrheic pigs.FEMS Microbiol. Lett.
152:307-312.[CrossRef][Medline]
- Dresden-Osborne,
C., G. Pittman-Noblet, E. N. Enongene, C. W. Bacon,
R. T. Riley, and K. A. Voss. 2002.
Host resistance to Trypanosoma cruzi infection is enhanced in
mice fed Fusarium verticillioides (=F. moniliforme)
culture material containing fumonisins. Food Chem.
Toxicol.
40:1789-1798.[CrossRef][Medline]
- Dupuy,
J., J. Le Bars, and P. Le Bars. 1992.
Mycotoxinogénèse de souches de Fusarium:
contrainte en vue de leur utilisation dans la lutte biologique.Cryptogam. Mycol.
13:159-169.
- Dutton,
M. F. 1996. Fumonisins, mycotoxins of
increasing importance: their nature and their effects.Pharmacol. Ther.
70:137-161.[CrossRef][Medline]
- Edrington,
T. S., C. A. Kamps-Holtzapple, R. B.
Harvey, L. F. Kubena, M. H. Elissalde, and
G. E. Rottinghaus. 1995. Acute hepatic and
renal toxicity in lambs dosed with fumonisin-containing culture
material. J. Anim. Sci.
73:508-515.[Abstract]
- Fairbrother,
J. M., and M. Ngeleka. 1994. Extraintestinal
E. coli infections in pigs, p.221
-236. In G. Gyles (ed.),
E. coli disease in animals. CAB International, Wallingford,
Oxon, United
Kingdom.
- Finks-Gremmels,
J. 1999. Mycotoxins: their implications for human and
animal health. Vet. Q.
21:115-120.[Medline]
- Fournout,
S., C. M. Dozois, M. Odin, C. Desautels, S. Peres, F.
Herault, F. Daigle, C. Segafredo, J. Laffitte, E. Oswald, J.
M. Fairbrother, and I. P. Oswald. 2000. Lack
of a role of cytotoxic necrotizing factor 1 toxin from Escherichia
coli in bacterial pathogenicity and host cytokine response in
infected germfree piglets. Infect. Immun.
68:839-847.[Abstract/Free Full Text]
- Fukata,
T., K. Sasai, E. Baba, and A. Arakawa. 1996. Effect of
ochratoxin A on Salmonella typhimurium-challenged layer
chickens. Avian Dis.
40:924-926.[CrossRef][Medline]
- Garabal,
J. I., E. A. González, F. Vazquez, J. Blanco,
and M. Blanco. 1995. Toxigenic Escherichia
coli in Spanish piggeries from 1986 to 1991. Vet.
Microbiol.
47:17-25.[CrossRef][Medline]
- Gumprecht,
L. A., V. R. Beasley, R. M. Weigel,
H. M. Parker, M. E. Tumbleson, C. W.
Bacon, F. I. Meredith, and W. M. Haschek.1998
. Development of fumonisin-induced hepatotoxicity and
pulmonary edema in orally dosed swine: morphological and biochemical
alterations. Toxicol. Pathol.
26:777-788.[Medline]
- Haschek
W. M., L. A. Gumprecht, G. Smith, M. E.
Tumbleson, and P. D. Constable. 2001.
Fumonisin toxicosis in swine: an overview of porcine pulmonary edema
and current perspectives. Environ. Health Perspect.
109(Suppl.
2):251-258.
- Howard,
P. C., R. M. Eppley, M. E. Stack, A.
Warbritton, K. A. Voss, R. J. Lorentzen,
R. M. Kovach, and T. J. Bucci.2001
. Fumonisin B1 carcinogenicity in a
two-year feeding study using F344 rats and B6C3F1 mice. Environ.
Health Perspect. 109(Suppl.
2):277-282.
- Johnson,
J. R., A. L. Stell, and P. Delavari.2001
. Canine feces as a reservoir of extraintestinal
pathogenic Escherichia coli. Infect. Immun.
69:1306-1314.[Abstract/Free Full Text]
- Khan,
A. S., B. Kniep, T. A. Oelschlaeger, I. Van Die, T.
Korhonen, and J. Hacker. 2000. Receptor structure for
F1C fimbriae of uropathogenic Escherichia coli. Infect.
Immun.
68:3541-3547.[Abstract/Free Full Text]
- Khan,
M. A. 1984. Minipig: advantages and
disadvantages as model in toxicity testing. J. Am.
Coll. Toxicol.
3:337-342.
- Kriek,
N. P. J., T. S. Kellerman, and
W. F. O. Marasas. 1981. A
comparative study of the toxicity of Fusarium moniliforme to
horses, primates, pigs, sheep and rats. Onderstepoort J. Vet.
Res.
48:129-131.[Medline]
- Kubena,
L. F., R. H. Bailey, J. A. Byrd,
C. R. Young, D. E. Corrier, L. H.
Stanker, and G. E. Rottinghaus. 2001. Cecal
volatile fatty acids and broiler chick susceptibility to Salmonella
typhimurium colonization as affected by aflatoxins and T-2 toxin.Poult. Sci.
80:411-417.[Abstract/Free Full Text]
- Le
Bars, J., P. Le Bars, J. Dupuy, H. Boudra, and R. Cassini.1994
. Biotic and abiotic factors in fumonisin
B1 production and stability. J. AOAC Int.
77:517-521.
- Li,
Y. C., D. R. Ledoux, A. J. Bermudez,
K. L. Fritsche, and G. E. Rottinghaus.1999
. Effects of fumonisin B1 on selected
immune responses in broiler chicks. Poult. Sci.
78:1275-1282.[Abstract/Free Full Text]
- Lingwood,
C. A. 1999. Glycolipid receptors for
verotoxin and Helicobacter pylori: role in pathology.Biochim. Biophys. Acta
1455:375-386.[Medline]
- Mannon,
J., and E. Johnson. 1985. Fungi down the farm.New Sci.
105:12-16.
- Marasas,
W. F., T. S. Kellerman, W. C. Gelderblom,
J. A. Coetzer, P. G. Thiel, and J. J. van
der Lugt. 1988. Leukoencephalomalacia in a horse
induced by fumonisin B1 isolated from Fusarium
moniliforme. Onderstepoort J. Vet. Res.
55:197-203.[Medline]
- Marin,
D. E., I. Taranu, R. P. Bunaciu, F. Pascale,
D. S. Tudor, N. Avram, M. Sarca, I. Cureu, R. D.
Criste, V. Suta, and I. P. Oswald. 2002.
Influence of low-level exposure to aflatoxin on performance, blood
parameters, humoral and cellular responses in weanling pigs. J.
Anim. Sci.
80:1250-1257.[Abstract/Free Full Text]
- Maxson,
R. T., R. J. Jackson, and S. D.
Smith. 1995. The protective role of enteral IgA
supplementation in neonatal gut origin sepsis. J.
Pediatr. Surg.
30:231-234.[CrossRef][Medline]
- Meivar-Levy,
I., and A. H. Futerman. 1999. Up-regulation
of neutral glycosphingolipid synthesis upon long term inhibition of
ceramide synthesis by fumonisin B1. J.
Biol. Chem.
274:4607-4612.[Abstract/Free Full Text]
- Merrill,
A. H., Jr., E. Wang, T. R. Vales, E. R.
Smith, J. J. Schroeder, D. S. Menaldino, C.
Alexander, H. M. Crane, J. Xia, D. C. Liotta,
F. I. Meredith, and R. T. Riley.1996
. Fumonisin toxicity and sphingolipid biosynthesis.Adv. Exp. Med. Biol.
392:297-306.[Medline]
- Miller,
E. R., and D. E. Ullrey. 1987. The
pig as a model for human nutrition. Annu. Rev. Nutr.
7:361-382.[CrossRef][Medline]
- Mims,
C. A. 1987. The pathogenesis of infectious
disease, 3rd ed. Academic Press, London, United
Kingdom.
- Mirocha,
C. J., H. K. Abbas, and R. F.
Vesonder. 1990. Absence of trichothecenes in toxigenic
isolates of Fusarium moniliforme. Appl. Environ.
Microbiol.
56:520-525.[Abstract/Free Full Text]
- Motelin,
G. K., W. M. Haschek, D. K. Ness,
W. F. Hall, K. S. Harlin, D. J.
Schaeffer, and V. R. Beasley. 1994. Temporal
and dose-response features in swine fed corn screenings contaminated
with fumonisin mycotoxins. Mycopathologia
126:27-40.[CrossRef][Medline]
- Murphy,
P. A., L. G. Rice, and P. F. Ross.1993
. Fumonisin B1, B2 and
B3 content of Iowa, Wisconsin and Illinois corn and corn
screening. J. Agric. Food Chem.
41:263-266.[CrossRef]
- Oswald,
I. P., and C. Comera. 1998. Immunotoxicity
of mycotoxins. Rev. Med. Vet.
149:585-590.
- Osweiler,
G. D. 2000. Mycotoxins. Contemporary issues
of food animal health and productivity. Vet. Clin. N. Am. Food
Anim. Pract.
16:511-530.[Medline]
- Osweiler,
G. D., P. F. Ross, T. M. Wilson,
P. E. Nelson, S. T. Witte, T. L. Carson,
L. G. Rice, and H. A. Nelson.1992
. Characterization of an epizootic of pulmonary edema
in swine associated with fumonisin in corn screenings. J. Vet.
Diagn. Investig.
4:53-59.[Abstract/Free Full Text]
- Rheeder,
J. P., W. F. O. Marasas, P. G.
Thiel, E. W. Sydenham, G. S. Shepard, and
D. J. van Schalkwyk. 1992. Fusarium
moniliforme and fumonisins in corn in relation to human esophagal
cancer in Transkei. Phytopathology
82:353-357.[CrossRef]
- Riley,
R. T., N. H. An, J. L. Showker,
H. S. Yoo, W. P. Norred, W. J.
Chamberlain, E. Wang, A. H. Merrill, Jr., G. Motelin,
V. R. Beasley, and W. M. Haschek.1993
. Alteration of tissue and serum sphinganine to
sphingosine ratio: an early biomarker of exposure to
fumonisin-containing feeds in pigs. Toxicol. Appl.
Pharmacol.
118:105-112.[CrossRef][Medline]
- Riley,
R. T., K. A. Voss, W. P. Norred,
R. P. Sharma, E. Wang, and A. H. Merrill.1998
. Fumonisins: mechanism of mycotoxicity. Rev.
Med. Vet.
149:617-626.
- Riley,
R. T., E. Enongene, K. A. Voss, W. P.
Norred, F. I. Meredith, R. P. Sharma, J.
Spitsbergen, D. E. Williams, D. B. Carlson, and
A. H. Merrill. 2001. Sphingolipid
perturbations as mechanisms for fumonisin carcinogenesis.Environ. Health Perspect.
109(Suppl.
2):301-308.
- Rotter,
B. A., B. K. Thompson, D. B. Prelusky,
H. L. Treeholm, B. Stewaer, J. D. Miller, and
M. E. Savard. 1996. Response of growing
swine to dietary exposure to pure fumonisin B1 during an
eight-week period: growth and clinical parameters. Nat.
Toxins
4:42-50.[Medline]
- Russo,
T. A., and J. R. Johnson. 2000.
Proposal for a new inclusive designation for extraintestinal pathogenic
isolates of Escherichia coli: ExPEC. J.
Infect. Dis.
181:1753-1754.[CrossRef][Medline]
- Sandvig,
K., O. Garred, A. van Helvoort, G. van Meer, and B. van Deurs.1996
. Importance of glycolipid synthesis for butyric
acid-induced sensitization to shiga toxin and intracellular sorting of
toxin in A431 cells. Mol. Biol. Cell
7:1391-1404.[Abstract]
- Scudamore,
K. A., S. Nawaz, and M. T. Hetmanski.1990
. Mycotoxins in ingredients of animal feeding stuffs:
II. Determination of mycotoxins in maize and maize products.Food Addit. Contam.
15:30-55.
- Shephard,
G. S., P. G. Thiel, S. Stockenstrom, and
E. W. Sydenham. 1996. Worldwide survey of
fumonisin contamination of corn and corn-based products. J. AOAC
Int.
79:671-687.[Medline]
- Smith,
G. W., P. D. Constable, A. R. Smith,
C. W. Bacon, F. I. Meredith, G. K.
Wollenberg, and W. M. Haschek. 1996. Effects
of fumonisin-containing culture material on pulmonary clearance in
swine. Am. J. Vet. Res.
57:1233-1248.[Medline]
- Smith,
H. 1992. Virulence determinants of Escherichia
coli: present knowledge and questions. Can. J.
Microbiol.
38:747-752.[Medline]
- Stoev,
S. D., D. Goundasheva, T. Mirtcheva, and P. G.
Mantle. 2000. Susceptibility to secondary bacterial
infections in growing pigs as an early response in ochratoxicosis.Exp. Toxicol. Pathol.
52:287-296.[Medline]
- Tai,
J. H., and J. J. Pestka. 1988.
Impaired murine resistance to Salmonella typhimurium following
oral exposure to the trichothecene T-2 toxin. Food Chem.
Toxicol.
26:691-698.[CrossRef][Medline]
- Tannock,
G. W. 1983. Effects of dietary and
environmental stress on the gastrointestinal microbiota, p.517
-539. In D. J.
Hentges (ed.), Human intestinal microflora in health and disease.
Academic Press, New York,
N.Y.
- Zomborszky,
M. K., F. Vetesi, I. Repa, F. Kovacs, A. Bata, P. Horn, A.
Toth, and R. Romvari. 2000. Experiment to determine
limits of tolerance for fumonisin B1 in weaned piglets.J. Vet. Med. Ser. B
47:277-286.
- Zomborszky-Kovacs,
M., F. Vetesi, P. Horn, I. Repa, and F. Kovacs. 2002.
Effects of prolonged exposure to low-dose fumonisin B1 in
pigs. J. Vet. Med. Ser. B
49:197-201.[CrossRef]
Applied and Environmental Microbiology, October 2003, p. 5870-5874, Vol. 69, No. 10
0099-2240/03/$08.00+0 DOI: 10.1128/AEM.69.10.5870-5874.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Accensi, F., Pinton, P., Callu, P., Abella-Bourges, N., Guelfi, J.-F., Grosjean, F., Oswald, I. P.
(2006). Ingestion of low doses of deoxynivalenol does not affect hematological, biochemical, or immune responses of piglets. J ANIM SCI
84: 1935-1942
[Abstract]
[Full Text]
-
Piva, A., Casadei, G., Pagliuca, G., Cabassi, E., Galvano, F., Solfrizzo, M., Riley, R. T., Diaz, D. E.
(2005). Activated carbon does not prevent the toxicity of culture material containing fumonisin B1 when fed to weanling piglets. J ANIM SCI
83: 1939-1947
[Abstract]
[Full Text]
-
Taranu, I., Marin, D. E., Bouhet, S., Pascale, F., Bailly, J.-D., Miller, J. D., Pinton, P., Oswald, I. P.
(2005). Mycotoxin Fumonisin B1 Alters the Cytokine Profile and Decreases the Vaccinal Antibody Titer in Pigs. Toxicol Sci
84: 301-307
[Abstract]
[Full Text]
-
Bouhet, S., Hourcade, E., Loiseau, N., Fikry, A., Martinez, S., Roselli, M., Galtier, P., Mengheri, E., Oswald, I. P.
(2004). The Mycotoxin Fumonisin B1 Alters the Proliferation and the Barrier Function of Porcine Intestinal Epithelial Cells. Toxicol Sci
77: 165-171
[Abstract]
[Full Text]